Prenatal Screening vs. Diagnostic Testing: Key Differences

Two Tests, Different Questions

Prenatal screening and diagnostic testing offer different kinds of information. Screening estimates whether a fetus has a higher chance of certain conditions; diagnostic testing can determine more definitively whether a specific condition is present. Understanding that distinction can make results easier to interpret and help guide conversations about next steps.

Screening can produce false-positive or false-negative results, so a clinician can explain what a particular finding means and whether further testing may be appropriate. The American College of Obstetricians and Gynecologists explains the difference between screening and diagnostic tests.

Prenatal testing is optional. The right choice depends on a patient’s circumstances, preferences, and how they might use the information. Raveco provides personalized obstetric care in Queens, where patients can discuss what each option can and cannot tell them with their care team. This article outlines those differences to support an informed, individual conversation, not to suggest that everyone should choose the same tests.

Screening Options and Their Purpose

Prenatal screening estimates the chance of selected conditions; it does not diagnose them. Tests may use a blood sample, ultrasound measurements, or both. A higher-risk result can prompt a discussion about diagnostic testing. ACOG’s guidance on prenatal genetic screening explains that both false-positive and false-negative results can occur.

Cell-free DNA (cfDNA), also called noninvasive prenatal testing (NIPT), analyzes small fragments of placental DNA in the pregnant person’s blood to estimate the risk of certain chromosome conditions. First-trimester screening combines a blood test with an ultrasound measurement called nuchal translucency, which measures the space at the back of the fetus’s neck. A second-trimester quad screen measures substances in the blood to assess risks that include some chromosome conditions and neural tube defects.

Ultrasound can also examine fetal structures, such as the heart, brain, spine, and limbs. Screening methods cover different conditions, and none checks for every possible concern. A prenatal care provider can explain what each test assesses and what its limitations mean for an individual pregnancy.

Carrier screening is different from fetal screening: it checks whether a prospective or pregnant parent carries gene changes associated with inherited conditions, such as cystic fibrosis or spinal muscular atrophy. If a parent is found to be a carrier, testing the other parent may help clarify the chance of passing on a condition.

Screening results can help patients decide whether to seek further evaluation, but they do not require a particular next step. At Raveco, prenatal care is centered on personalized obstetrics and gynecology services in Queens, where patients can discuss testing choices and follow-up with their care team. Diagnostic procedures such as CVS or amniocentesis can provide more definitive information about specific conditions, but involve sampling placental tissue or amniotic fluid and have risks to review with a clinician. Cleveland Clinic’s overview of pregnancy genetic testing describes these options and the role of follow-up after a higher-risk screen.

Timing and What Results Mean

The right testing window depends on the method and the pregnancy. Cell-free DNA (cfDNA), also called noninvasive prenatal testing (NIPT), can generally begin at about 10 weeks. First-trimester screening is commonly done around 11–13 weeks, while chorionic villus sampling (CVS), a diagnostic procedure, is generally performed around 10–13 weeks. ACOG’s screening guidance describes these screening windows and options.

Amniocentesis is usually performed from about 15 weeks onward, commonly within the 15–20-week range. Quad screening takes place in the second trimester; sources give windows that vary, including about 16–18 weeks and a broader range extending to 22 weeks. Your clinician can confirm which dates apply to the specific test and your circumstances. The timing of prenatal tests can also help frame questions for that discussion.

A cfDNA test analyzes small fragments of placental DNA circulating in the pregnant person’s blood. It estimates the chance of selected chromosome-number conditions, such as Down syndrome, trisomy 18, and trisomy 13, and may also provide information about fetal sex. Because it is a screening test, a higher-risk result does not confirm a condition.

Accuracy and limitations differ by test, so ask your care team what a result can and cannot tell you. A higher-risk finding may prompt a conversation about diagnostic testing, but whether to pursue further testing is a personal decision. At Raveco, prenatal care is provided through a personalized obstetrics and gynecology practice in Queens, where patients can discuss testing options in the context of their care.

Interpreting Conditions and Accuracy

Prenatal tests look for selected conditions, not every genetic difference or structural concern. Screening may estimate risk for Down syndrome, trisomy 18, trisomy 13, and, depending on the test, neural tube defects or other structural concerns. Some screening options assess risk for inherited conditions, but the conditions covered vary by test. ACOG’s guide to prenatal genetic screening explains that screening cannot identify every possible condition.

Screening results estimate likelihood; they do not confirm a diagnosis. If more definitive information is needed, diagnostic testing can analyze cells from the placenta through chorionic villus sampling (CVS) or from amniotic fluid through amniocentesis. These tests can assess specific chromosomal or inherited conditions, but their scope also depends on the analysis ordered. ACOG’s guidance on prenatal diagnostic testing describes the role and limits of diagnostic testing.

How accurate a result is depends on the test and condition being assessed. A higher-risk screening result may be a false positive. If a result is inconclusive, ask what that means for the specific test and whether follow-up is appropriate. Patients receiving personalized obstetric care at Raveco in Queens can discuss test coverage, limitations, and results with their care team. For more on conditions prenatal testing may detect, ask which findings apply to the test being considered.

Diagnostic Procedures And Considerations

When screening suggests an increased chance of a condition, diagnostic testing may offer more definitive information. Whether to proceed depends on what a patient wants to learn and the benefits and limitations of each option, as explained in ACOG’s guidance on prenatal diagnostic testing.

How CVS and amniocentesis differ

Chorionic villus sampling (CVS) collects a small sample of placental tissue, generally around 10 to 13 weeks. The sample may be taken through the abdomen or vagina, depending on what is safest. Amniocentesis collects a small amount of amniotic fluid with a needle through the abdomen, generally around 15 to 20 weeks. Ultrasound may guide these procedures. Both can assess specific genetic or chromosomal conditions, but the clinician should explain which conditions a proposed test can evaluate.

Because CVS and amniocentesis involve procedures inside the uterus, risks can include miscarriage, bleeding, and infection. The likelihood depends on the procedure and individual circumstances. A conversation with the care team can clarify how those risks compare with the value of a more definitive result; diagnostic procedures are not necessary for every patient.

Before deciding, patients can ask what the test may and may not show, when results are expected, and how the findings could inform care. Personalized obstetric care, such as that provided at Raveco in Queens, can support discussion of testing choices in light of a patient’s health history and preferences.

After a procedure, follow the instructions from the clinician who performed it, since the available guidance does not establish one set of aftercare steps for everyone. Ask whom to contact with questions about recovery or symptoms, and when to expect results. Your care team can provide advice suited to the specific procedure and pregnancy.

Making a Personal Testing Decision

Prenatal genetic testing is optional, and there is no single right choice for every pregnancy. The American College of Obstetricians and Gynecologists says patients may accept or decline screening and diagnostic testing after counseling about their options and circumstances (ACOG guidance).

A conversation with an obstetric clinician can take account of your medical and family history, pregnancy circumstances, and what you hope to learn. Ask what a test can and cannot detect, how reliable its results are, and how you might use the information in planning care.

Screening estimates risk, while diagnostic testing can provide more definitive information and involves an invasive procedure with possible complications. If a screen indicates higher risk, a clinician or genetic counselor can explain whether diagnostic testing is an option, along with its benefits and limitations. At Raveco, prenatal care is centered on individualized support, giving patients space to discuss questions and preferences with their care team.

The decision belongs to you. Informed choices can reflect your goals, values, and comfort with uncertainty, whether you choose screening, diagnostic testing, or neither.

Support Throughout Your Decision

Neither choice is right for everyone, and testing is optional.

At Raveco, prenatal care is personalized to each patient’s circumstances. Ask your pregnancy care provider or a genetic counselor about timing, test accuracy, possible risks, and what follow-up could involve. ACOG’s guidance on prenatal genetic screening can also help clarify what results do and do not mean.

You can choose the information and care pathway that best fits your health, values, and needs. A thoughtful conversation can help you make that choice with support.